tiprankstipranks
Trending News
More News >
Virbac SA (FR:VIRP)
:VIRP

Virbac SA (VIRP) AI Stock Analysis

Compare
9 Followers

Top Page

FR

Virbac SA

(LSE:VIRP)

Rating:76Outperform
Price Target:
€390.00
▲(15.56%Upside)
Virbac SA's strong financial performance is the primary driver of its overall stock score, supported by stable cash flows and low leverage. Although the technical analysis indicates potential overbought conditions, the general momentum remains positive. The fair valuation further bolsters the company's attractiveness, especially for growth-focused investors.
Positive Factors
Regional Performance
Europe and Latin America are demonstrating solid growth rates of around 8%, contributing positively to Virbac's overall performance.
Sales Growth
Virbac's first-quarter sales figures showed organic growth of 4.9%, aligning with expectations and indicating a promising start to the year.
Negative Factors
Earnings Growth
A slowdown in earnings growth is anticipated to continue due to an unfavourable base effect, which may affect investor sentiment.
Regional Challenges
Australia's market conditions are unfavourable, causing a sharp decline of 15% in the region and negatively impacting Virbac's overall sales.

Virbac SA (VIRP) vs. iShares MSCI France ETF (EWQ)

Virbac SA Business Overview & Revenue Model

Company DescriptionVirbac SA is a global animal health company that develops, manufactures, and distributes a comprehensive range of products and services for veterinarians, livestock farmers, and pet owners. The company's offerings include vaccines, pharmaceuticals, and nutritional products for both companion animals and livestock, catering to the health and well-being of animals across various species.
How the Company Makes MoneyVirbac SA generates revenue through the sale of its diverse portfolio of animal health products, catering to both companion animals and livestock. Key revenue streams include veterinary pharmaceuticals, vaccines, and nutritional products. The company focuses on developing innovative solutions to meet the evolving needs of the animal health industry, leveraging research and development to create advanced products. Additionally, Virbac engages in strategic partnerships and collaborations with veterinary clinics, distributors, and research institutions, which help in expanding market reach and enhancing product offerings. These partnerships, along with a robust distribution network, play a significant role in driving the company's earnings.

Virbac SA Financial Statement Overview

Summary
Virbac SA demonstrates a strong financial profile with consistent revenue growth, robust profitability margins, and minimal leverage. The company effectively manages costs and utilizes shareholder equity efficiently, while maintaining solid cash flow generation.
Income Statement
85
Very Positive
Virbac SA demonstrates a strong income statement with consistent revenue growth over the years. Gross Profit Margin in 2024 is approximately 67.4%, reflecting efficient cost management. Net Profit Margin stands at about 10.4%, indicating a solid profitability level. EBIT Margin of 15.5% and EBITDA Margin of 20.4% showcase robust operational efficiency. Revenue grew by approximately 12.1% from 2023 to 2024, indicating a healthy upward trajectory. Overall, the company shows strong profitability and growth, with a continuous positive trend.
Balance Sheet
80
Positive
The balance sheet of Virbac SA is stable with a low Debt-to-Equity Ratio of 0.04, indicating minimal leverage and financial risk. Return on Equity (ROE) is approximately 13.9%, showcasing effective utilization of shareholder equity to generate profits. The Equity Ratio of 56.4% suggests a solid capital structure with a significant portion of assets financed by equity. These metrics indicate financial stability and a well-managed balance sheet with minimal debt risk.
Cash Flow
78
Positive
Virbac SA's cash flow statement shows solid cash generation capabilities with a Free Cash Flow Growth Rate of approximately 128.5% from 2023 to 2024. The Operating Cash Flow to Net Income Ratio is about 1.4, indicating good cash conversion. Free Cash Flow to Net Income Ratio stands at 0.93, reflecting efficient management of capital expenses. The company exhibits strong cash flow management, though a higher free cash flow conversion ratio would further enhance its cash flow position.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.40B1.25B1.22B1.06B934.20M
Gross Profit937.60M422.67M427.27M378.38M290.41M
EBITDA284.85M230.65M215.55M199.46M231.67M
Net Income145.29M121.30M121.97M113.16M136.04M
Balance Sheet
Total Assets1.85B1.46B1.36B1.22B1.11B
Cash, Cash Equivalents and Short-Term Investments149.63M175.91M177.38M172.79M181.89M
Total Debt307.01M120.11M91.49M95.37M116.22M
Total Liabilities805.12M545.81M521.17M498.84M454.28M
Stockholders Equity1.04B900.30M839.33M724.93M620.97M
Cash Flow
Free Cash Flow134.97M59.06M45.41M79.13M81.23M
Operating Cash Flow204.22M118.64M98.98M126.29M110.22M
Investing Cash Flow-428.69M-121.87M-54.83M-106.22M339.52M
Financing Cash Flow138.59M-2.56M-34.76M-33.07M-341.19M

Virbac SA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price337.50
Price Trends
50DMA
316.24
Positive
100DMA
309.27
Positive
200DMA
322.38
Positive
Market Momentum
MACD
3.47
Negative
RSI
62.65
Neutral
STOCH
60.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VIRP, the sentiment is Positive. The current price of 337.5 is above the 20-day moving average (MA) of 320.91, above the 50-day MA of 316.24, and above the 200-day MA of 322.38, indicating a bullish trend. The MACD of 3.47 indicates Negative momentum. The RSI at 62.65 is Neutral, neither overbought nor oversold. The STOCH value of 60.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:VIRP.

Virbac SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
€2.83B19.4514.95%0.43%12.07%20.48%
76
Outperform
€903.52M15.3610.64%1.16%1.88%5.79%
FRSAN
71
Outperform
$101.57B18.757.34%4.71%-4.62%2.88%
FRIPN
70
Outperform
€8.56B24.768.89%1.35%8.73%-46.34%
FRBOI
62
Neutral
€395.92M34.612.94%4.63%-1.15%-68.36%
55
Neutral
€4.86B18.25-49.50%1.91%13.92%-4.82%
37
Underperform
€556.88M
-1.66%-6.31%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:VIRP
Virbac SA
337.50
-10.93
-3.14%
FR:VETO
VETOQUINOL
76.40
-16.78
-18.01%
FR:IPN
Ipsen
102.50
-6.62
-6.07%
FR:SAN
Sanofi
82.44
-5.77
-6.55%
FR:BOI
Boiron SA
22.60
-7.91
-25.92%
FR:MEDCL
MedinCell SA
16.84
1.98
13.32%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 04, 2025